Thomas Davis, MD
Cardiovascular Disease · St Clair Shores, MINPI 1184673303
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 17.6%. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 806 payments — averaging $157.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$22K
- Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$19K
- Cardiovascular Systems Inc.$13K
- Stryker$12K
- Avinger Inc.$9K
- Cordis US CORP.$9K
- plus $43K from 43 others
Across 174 payments — averaging $2653.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$341K
- Endologix LLC$37K
- Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$35K
- Cagent Vascular Inc$18K
- Inspiremd Ltd$9K
- Abbott$7K
- plus $14K from 4 others
Across 2 payments — averaging $16,405 each. An ownership or investment interest held by the physician or an immediate family member.
- Verge Medical, Inc.$33K
- Cardio Flow, Inc.$0
What the payments were for
- Consulting fees$59,13446%
- Speaking & faculty fees$24,58019%
- Travel & lodging$11,3459%
- Food & beverage$32,22825%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DABRA 101 Catheter$18,288
- FLOWTRIEVER CATHETER, S$16,333
- CT THROMBECTOMY SYSTEM KIT$16,333
- Peripheral Orbital Atherectomy System$11,265
- Tack Endovascular System$8,301
- MYNX CONTROL$6,625
- PANTHERIS$4,905
- Serrantor$2,595
- Coronary Orbital Atherectomy System$2,018
- COREVALVE EVOLUT R$1,554
- Rotarex$1,450
- CLOTTRIEVER BOLD CATHETER$837
- CoreValve Evolut$769
- EKOSONIC$720
- Venclose Maven Catheter$684
- LUTONIX$594
- Impella$541
- BRITE TIP RADIANZ$500
- BRITE TIP$500
- LIMFLOW SYSTEM$431
How this compares
$127,288 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 219 | $248,093 |
| XareltoRivaroxaban | 53 | $68,529 |
| EntrestoSacubitril/Valsartan | 64 | $64,061 |
| Repatha SureclickEvolocumab | 16 | $13,067 |
| Metoprolol Succinate | 335 | $6,448 |
| Atorvastatin Calcium | 447 | $6,059 |
| ClopidogrelClopidogrel Bisulfate | 244 | $4,090 |
| Ranolazine ErRanolazine | 14 | $2,724 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 118 | $2,701 |
| Losartan Potassium | 187 | $2,572 |
| Cilostazol | 127 | $2,478 |
| Lisinopril | 237 | $2,265 |
| Carvedilol | 135 | $2,133 |
| Hydralazine Hcl | 91 | $2,011 |
| Rosuvastatin Calcium | 112 | $1,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $227 | $248,093219 claims |
| Johnson & JohnsonXarelto | $488 | $68,52953 claims |
| NovartisEntresto | $370 | $64,06164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in St Clair Shores
- Thomas LalondeSt Clair Shores$65K
- Marc GosselinSt Clair Shores$43K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.